Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies

Review

Abstract

A systematic review of matched cohort and case-control studies was performed to examine the mortality attributable to candidemia. The review included studies that compared mortality of patients with candidemia (cases) to that of matched patients without candidemia (controls). Secondary variables examined were the length and cost of hospital stay. Relevant studies were identified using the PubMed database and by examining the references of the initially selected studies. Two independent reviewers performed the literature search, study selection and data extraction from the identified studies. A total of seven studies were included in the review. The patients included those hospitalized in intensive care units (ICU) and hospital wards and those undergoing transplantation. The mortality attributed to candidemia in the reviewed studies ranged from 5 to 71%. For six of the reviewed studies the difference in mortality between cases and controls was statistically significant. Among those who survived, the length of stay and the cost of hospitalization of patients with candidemia were significantly higher than those of controls. Despite the methodological heterogeneity of the reviewed studies, the data from the available matched cohort and case-control studies suggest that candidemia is associated with considerable mortality that is attributed, at least to some degree, to the infection itself and not only to the presence of another comorbidity.

References

  1. 1.
    Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals (2002) Secular trends of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630PubMedCrossRefGoogle Scholar
  2. 2.
    National Nosocomial Infection Surveillance (NNIS) (1999) System report, data summary from January1990–May 1999, issued June 1999. Am J Infect Control 27:520–532CrossRefGoogle Scholar
  3. 3.
    Beck-Sague C, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990: National Nosocomial Infection Surveillance System. J Infect Dis 167:1247–1251PubMedGoogle Scholar
  4. 4.
    Edmond MB, Wallace SE, McClisch DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in the United States hospitals: a three-year analysis. Clin Infect Dis 29:239–244PubMedCrossRefGoogle Scholar
  5. 5.
    Caroll K, Jeppson K, Reading J, Reimer L (1993) Factors influencing outcome in hospitalized patients with candidemia. Infect Dis Clin Pract 2:268–271CrossRefGoogle Scholar
  6. 6.
    Jarvis WR (1995) Epidemiology of nosocomial fungal infections with emphasis on Candida species. Clin Infect Dis 20:1526–1530PubMedGoogle Scholar
  7. 7.
    Pfaller M, Wenzel P (1992) Impact of changing epidemiology of fungal infections in the 1990s. Eur J Clin Micribiol Infect Dis 11:287–291CrossRefGoogle Scholar
  8. 8.
    Wenzel RP (1995) Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20:1531–1534PubMedGoogle Scholar
  9. 9.
    Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsh SM (2005) Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26:540–547PubMedCrossRefGoogle Scholar
  10. 10.
    Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232–1239PubMedCrossRefGoogle Scholar
  11. 11.
    Blot SI, Vandewoude KH, Hoste EA, Colardyn FA (2002) Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 113:480–485PubMedCrossRefGoogle Scholar
  12. 12.
    Gudlaugsson O, Gillespie S, Lee K, Berg JV, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172–1177PubMedCrossRefGoogle Scholar
  13. 13.
    Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645PubMedCrossRefGoogle Scholar
  14. 14.
    Nieto-Rodriguez JA, Kusne S, Mañez R, Irish W, Linden P, Magnone M, Wing EJ, Fung JJ, Starzl TE (1996) Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 223:70–76PubMedCrossRefGoogle Scholar
  15. 15.
    Puzniak L, Teutsch S, Powderly W, Polish L (2004) Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 25:628–633CrossRefGoogle Scholar
  16. 16.
    DiGiovine B, Chenoweth C, Watts C, Higgins M (1999) The attributable mortality and costs of primary nosocomial blood stream infections in the intensive care unit. Am J Respir Crit Care Med 160:976–981PubMedGoogle Scholar
  17. 17.
    Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645PubMedCrossRefGoogle Scholar
  18. 18.
    Blot SI, Vandewounde KH (2003) Estimating attributable mortality of candidemia: clinical judgement vs. matched cohort studies. Eur J Clin Micribiol Infect Dis 22:132–133Google Scholar
  19. 19.
    Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE, Infectious Diseases Society of America (2004) Guidelines from the Infectious Diseases Society of America: guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • M. E. Falagas
    • 1
    • 2
  • K. E. Apostolou
    • 1
  • V. D. Pappas
    • 1
  1. 1.Alfa Institute of Biomedical Sciences (AIBS)AthensGreece
  2. 2.Department of MedicineTufts University School of MedicineBostonUSA

Personalised recommendations